Arcutis Biotherapeutics, Inc. (ARQT) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary highlights a 65% increase in net product revenues driven by increased demand and improved payer contracting. Despite higher R&D and SG&A expenses, the company maintains positive cash flow and anticipates stable gross-to-net percentages. The Q&A section reveals strong Q2 sales growth, impressive prescription trends, and strategic market expansion plans. The management's optimistic guidance and robust market strategy suggest a positive sentiment. Given the small-cap market cap of $1.09 billion, the stock price is likely to react positively within the 2% to 8% range over the next two weeks.
Key Financial Performance
Net Product Revenues $105.4 million, up 65% versus the first quarter of 2025. The increase was driven primarily by increased patient demand and lower gross to net in the first quarter of 2026 versus a year earlier, due to the evolution of payer contracting.
Cost of Sales $9.8 million compared to $8.8 million in the first quarter of 2025, primarily due to increasing ZORYVE sales volume.
R&D Expenses $30.6 million versus $17.5 million for the corresponding period in 2025. The increase was primarily due to a $10 million milestone obligation to Ducentis shareholders triggered by the dosing of the first subject in the ARQ-234 Phase I trial.
SG&A Expenses $74.1 million for the first quarter of 2026 compared to $64 million in the same period last year, up 16% as the company continues to invest in commercialization efforts for ZORYVE.
Cash and Marketable Securities $224.3 million as of March 31, 2026. The company maintained positive cash flow in the quarter with $2.2 million of net cash provided by operating activities.
Total Debt $101.5 million with the right to withdraw another $50 million in whole or in part at the company's discretion through the middle of 2026.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
ZORYVE cream 0.05%: Submitted a supplemental NDA for atopic dermatitis patients aged 3 to 24 months. Completed enrollment in a MUSE trial for ZORYVE foam 0.3% in children with scalp and body psoriasis ages 2 to 11 years.
ZORYVE foam 0.3%: Trial completed for children ages 2 to 11 years with scalp and body psoriasis. Supplemental NDA for ZORYVE cream 0.3% for psoriasis patients down to age 2 under review with a PDUFA action date of June 29.
ARQ-234: Initiated Phase Ia and Phase Ib trials targeting CD200R for moderate to severe atopic dermatitis.
Dermatology sales force expansion: Expanded dermatology sales force to enhance reach. Began building a dedicated PCP and pediatric sales team.
Direct-to-consumer campaign: Launched 'Free to Be Me' campaign featuring Tori Spelling and others to drive awareness for ZORYVE.
Revenue growth: Net product revenues of $105.4 million in Q1 2026, up 65% from Q1 2025. Gross to net rate improved compared to Q1 2025.
Cash flow: Maintained positive cash flow in Q1 2026 with $2.2 million net cash provided by operating activities.
Shift from topical steroids: Growing consensus among dermatologists to prefer advanced nonsteroidal topicals like ZORYVE over topical corticosteroids for long-term management.
Pipeline development: Progress in Phase II proof-of-concept trials for vitiligo and hidradenitis suppurativa. Exploring additional Phase II trials for other indications.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Seasonality and Weather Impact: The company experienced a significant sequential decline in product revenues from Q4 2025 to Q1 2026 due to typical seasonality, compounded by severe weather events across the country. This could impact revenue predictability and operational planning.
Gross-to-Net Stability: While gross-to-net rates remained stable in the 50s, there is a dependency on evolving payer contracting to maintain or improve these rates. Any unfavorable changes in payer dynamics could adversely affect financial performance.
Sales Force Expansion: The expansion of the dermatology sales force and the build-out of a primary care and pediatric team require time for new hires to become effective. This delay could impact the anticipated sales growth timeline.
Regulatory Approvals: The company is awaiting FDA approval for supplemental NDAs for ZORYVE in various indications. Delays or rejections in these approvals could hinder market expansion and revenue growth.
Pipeline Development: The company is investing heavily in pipeline development, including Phase I trials for ARQ-234 and Phase II trials for vitiligo and hidradenitis suppurativa. Any setbacks in clinical trials could delay product launches and impact long-term growth.
Economic and Market Conditions: The shift from topical steroids to branded nonsteroidal topicals is a key growth driver. However, economic uncertainties or changes in market dynamics could slow this transition, affecting demand for ZORYVE.
Cash Flow Management: While the company has achieved positive cash flow, maintaining this status requires disciplined expense management. Any unforeseen expenses or revenue shortfalls could disrupt this balance.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Guidance: The company is maintaining its revenue guidance in the range of $480 million to $495 million for the full year 2026.
Gross to Net Adjustments: Gross to net rate is expected to remain in the 50s throughout 2026, ending in the low 50s.
ZORYVE Demand Growth: Sustained demand growth is anticipated to be the primary driver of ZORYVE's revenue expansion for the remainder of 2026.
Sales Force Expansion Impact: The expanded dermatology sales force is expected to impact demand growth starting in the third quarter of 2026, with primary care and pediatric sales team efforts contributing later in 2026 and into 2027.
Pipeline Development: The company is progressing with Phase II proof-of-concept trials in vitiligo and hidradenitis suppurativa, with results expected in Q4 2026 and Q1 2027, respectively. A Phase I trial for ARQ-234 is ongoing, targeting moderate to severe atopic dermatitis.
ZORYVE Label Expansion: A supplemental NDA for ZORYVE cream 0.05% for infants aged 3 to 24 months with atopic dermatitis has been submitted, with potential approval expanding its use. A PDUFA action date for ZORYVE cream 0.3% for psoriasis patients down to age 2 is set for June 29, 2026.
Operating Leverage Expansion: The company anticipates meaningful operating leverage expansion and cash flow generation starting in 2027, driven by ZORYVE's growth and moderated investment needs.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What drove the better gross-to-net percentage compared to Q1 of last year, and what impact could it have for the rest of the year?
A:The improvement was driven by better formulary status with more preferred positions in commercial plans, leading to lower co-pay expenses and buy-downs. Management anticipates gross-to-net to remain stable in the 50s throughout the year, transitioning from higher 50s to lower 50s as deductibles are met.
Q:What was the quarter-over-quarter impact of Q1 seasonality compared to Q4, and how does management view Q2 sales?
A:Q1 seasonality was impacted by gross-to-net improvements, weather, and deductible resets. Q2 sales are off to a strong start with 13% growth quarter-to-date through April 24, and management expects robust quarter-over-quarter growth.
Q:What assumptions drive the lower end of this year's sales guidance, and why is the upper end challenging to achieve?
A:Management updated guidance in February and does not plan to revise it quarterly. They are monitoring trends and may adjust guidance later in the year. For now, they suggest leaning into the upper end of the guidance.
Q:What are the trends in new prescriptions (NRx) and total prescriptions (TRx) for ZORYVE?
A:ZORYVE drove 48% of new-to-brand prescriptions for branded non-steroidal topicals in Q1. NRx was flat quarter-over-quarter, and refills accounted for 45% of total prescriptions. Recent weeks in Q2 show impressive NRx growth, indicating strong TRx growth ahead.
Q:What is the opportunity in the infant atopic dermatitis market, and how will the company capture it?
A:The market includes 2-2.5 million patients. The company plans to leverage both dermatology and primary care sales forces, along with direct-to-consumer campaigns targeting caregivers, to drive awareness and adoption of ZORYVE.
Q:Why was SG&A lower than expected in Q1, and what is the expected spending cadence for the year?
A:SG&A was slightly below consensus due to timing. Spending will normalize in Q2 with the sales force expansion and increase modestly in the second half of the year due to additional initiatives and campaigns.
Q:What progress is expected in Medicaid and Medicare coverage for ZORYVE, and how does the sales force expansion target lower decile prescribers?
A:Medicaid coverage progress is expected in 2026, while Medicare coverage may take until 2027 but could be pulled forward. The sales force expansion will focus on medium decile prescribers with high patient loads and willingness to adopt branded products.
Q:What is the company doing differently in the primary and pediatric care settings compared to CALA?
A:The company is focusing on high-opportunity primary care and pediatric targets with high patient loads and a history of adopting branded products. They aim to ensure sufficient frequency of engagement to drive adoption.
Q:What efficacy benchmarks are needed for the foam in vitiligo and hidradenitis suppurativa (HS) to continue development?
A:For vitiligo, the focus is on response timing compared to Opzelura. For HS, the goal is to assess effectiveness in early-stage disease and as an adjunct to systemic therapies, given the limited efficacy of current systemic treatments.
Q:Review of Unclear Management Responses
A:Management avoided directly addressing the question about the assumptions driving the lower end of the sales guidance and why the upper end is challenging to achieve. They deferred to monitoring trends and suggested leaning into the upper end without providing specific details.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Arcutis
HS
INTEGUMENT
Slide
ZORYVE cream
ZORYVE itch
age group
application
care
caregiver
cash flow
child
component
corticosteroid
demand
dermatitis
dermatology
disease
effort
expansion
field
franchise
improvement
indication
infant
investment
month
need
option
patient
pillar
population
prescription
product
progress
psoriasis
sale force
seasonality
therapy
treatment
trial
week
ARQT Transcript
Arcutis Biotherapeutics, Inc. (ARQT) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Neutral6-9
Arcutis Biotherapeutics, Inc. (ARQT) Q1 2026 Earnings Call Transcript
Positive5-7
The earnings call summary highlights a 65% increase in net product revenues driven by increased demand and improved payer contracting. Despite higher R&D and SG&A expenses, the company maintains positive cash flow and anticipates stable gross-to-net percentages. The Q&A section reveals strong Q2 sales growth, impressive prescription trends, and strategic market expansion plans. The management's optimistic guidance and robust market strategy suggest a positive sentiment. Given the small-cap market cap of $1.09 billion, the stock price is likely to react positively within the 2% to 8% range over the next two weeks.
Arcutis Biotherapeutics, Inc. (ARQT) Q4 2025 Earnings Call Transcript
Positive2-26
The earnings call summary indicates a positive sentiment due to a 20% revenue increase and a 10% improvement in net loss, suggesting strong product sales and cost efficiency. Although cash reserves decreased, this was due to strategic investments. The lack of explicit or implied risks and the absence of concerning Q&A responses further support a positive outlook. Given the small-cap status, the stock price is likely to react positively, falling within the 2% to 8% range.
Arcutis Biotherapeutics, Inc. (ARQT) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)
Neutral9-9
ARQT Slides
ARQT Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
